Jyoti D. Patel, MD, and Rajat Thawani, MBBS, tackle the question of whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable non–small cell lung cancer.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.